The Landmark HORIZONS-AMI Trial: Final 3 Year Results
Links shared publicly online about this topic.
- 219total visits
The Landmark HORIZONS-AMI Trial: Final 3 Year Results
View full resource at medicalnewstoday.com
Tags: Heart, Drug, Clinical Trial, Anti-Clotting Medication, Anticoagulant
Most Recently Shared on June 14, 2011 at 4:05 pm By:
The Landmark HORIZONS-AMI Trial: Final 3 Year Results http://mnt.to/3X98 #medicaldevices
Also Shared By:
Family Medicine Article | Myocardial Infarction
mdlinx.com — “Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial” View full resource at mdlinx.com
Most Recently Shared on June 25, 2011 at 4:44 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-elutin... http://bit.ly/iIzluk #FamPractice
The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial
news-medical.net — “Data from the landmark HORIZONS-AMI clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a glycoprotein (GP) IIb/IIIa inhibitor in heart attack patients undergoing angioplasty after 3 years. Use of a drug-eluting stent was also shown to be more effective than a bare-metal stent, with equivalent safety.” View full resource at news-medical.net
Most Recently Shared on June 14, 2011 at 3:20 pm By:
Stroke News: The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial: Data from the l... http://twurl.nl/fs7hxl
The Landmark HORIZONS-AMI Trial: Final 3 Year Results
medicalnewstoday.com — “Data from the landmark HORIZONS-AMI clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a glycopr” View full resource at medicalnewstoday.com
Most Recently Shared on June 14, 2011 at 1:08 pm By:
Drugs and Devices OW OW Health
The Landmark HORIZONS-AMI Trial: Final 3 Year Results: Data from the landmark HORIZONS-AMI clinical t... http://bit.ly/jU9lDM #MedDevice
Final 3-year results from the landmark HORIZONS-AMI trial
sciencedaily.com — “Data from the landmark HORIZONS-AMI clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a glycoprotein IIb/IIIa inhibitor in heart attack patients undergoing angioplasty after 3 years. Use of a drug-eluting stent (paclitaxel) was also shown to be more effective than a bare-metal stent, with equivalent safety.” View full resource at sciencedaily.com
Most Recently Shared on June 13, 2011 at 9:41 pm By:
ScienceDaily: Final 3-year results from the landmark HORIZONS-AMI trial http://bit.ly/l4fWKY Full http://bit.ly/lDE8A4
Angiomax Reduced Cardiac Mortality By 41%; Reduced Overall Mortality By 25% In Severe Heart Attack Patients Following Angioplasty
medicalnewstoday.com — “The medicines company (nasdaq: mdco) today announced the presentation of 2-year clinical results from the landmark horizons-ami trial. the trial showed that patients who had suffered the most seve” View full resource at medicalnewstoday.com
Most Recently Shared on September 28, 2009 at 12:12 pm By:
MedicalNewsToday: Angiomax Reduced Cardiac Mortality By 41%; Reduced Overall Mortality By 25% http://bit.ly/1hTb6s Full http://bit.ly/eGYQp
Advertisement
MNT Cardiovascular
@mnt_cardiovasc
Angiomax Reduced Cardiac Mortality By 41%; Reduced Overall Mortality By 25% In Severe Heart Attack Patients Fol.. http://bit.ly/3zYGaW
1 year ago...